首页> Molecular genetics and metabolism> Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio

导出原文传递

翻译打印收藏纠错

第一作者： M. Mokhtarani

作者： M. Mokhtarani ^[1] ; G.A. Diaz ; W. Rhead ; S.A. Berry ; U. Lichter-Konecki ; A. Feigenbaum ; A. Schulze

作者单位： Hyperion Therapeutics, 601 Gateway Blvd., Suite 200, South San Francisco, CA 94080, USA ^[1]

关键词 BUPHENYL Glycerol phenylbutyrate HPN-100 Neurological adverse events RAVICTI Sodium phenylbutyrate

发布时间 2014-05-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Molecular genetics and metabolism

2013年110卷4期

446-453页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

Molecular genetics and metabolism

2013年110卷4期

446-453页

检索历史清除

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio

Molecular genetics and metabolism

相似文献

同项目论文

Molecular genetics and metabolism

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio

Molecular genetics and metabolism

相似文献

同项目论文

Molecular genetics and metabolism

相关期刊

检索历史清除